These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 30758879)
1. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab. Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879 [No Abstract] [Full Text] [Related]
2. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII. Wada N; Uchi H; Furue M J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843 [No Abstract] [Full Text] [Related]
3. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature. Cosimati A; Rossi L; Didona D; Forcella C; Didona B J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795 [TBL] [Abstract][Full Text] [Related]
4. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report. Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068 [No Abstract] [Full Text] [Related]
5. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer. Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550 [No Abstract] [Full Text] [Related]
6. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Parakh S; Nguyen R; Opie JM; Andrews MC Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423 [TBL] [Abstract][Full Text] [Related]
7. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425 [No Abstract] [Full Text] [Related]
8. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system. Aggarwal P Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310 [No Abstract] [Full Text] [Related]
9. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. Bandino JP; Perry DM; Clarke CE; Marchell RM; Elston DM J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e378-e380. PubMed ID: 28222231 [No Abstract] [Full Text] [Related]
10. Bullous pemphigoid probably associated with pembrolizumab: a case of delayed toxicity. Correia C; Fernandes S; Soares-de-Almeida L; Filipe P Int J Dermatol; 2022 Apr; 61(4):e129-e131. PubMed ID: 34289119 [No Abstract] [Full Text] [Related]
11. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab. Sato Y; Fujimura T; Mizuashi M; Aiba S J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404 [No Abstract] [Full Text] [Related]
12. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067 [No Abstract] [Full Text] [Related]
13. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab. Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534 [No Abstract] [Full Text] [Related]
14. Generalized morphea in the setting of pembrolizumab. Cheng MW; Hisaw LD; Bernet L Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792 [No Abstract] [Full Text] [Related]
15. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. Bezinelli LM; Eduardo FP; Migliorati CA; Ferreira MH; Taranto P; Sales DB; Santi CG; Macarenco RS; Godoy CPV; CorrĂȘa L; Buzaid AC J Immunother; 2019; 42(9):359-362. PubMed ID: 31246641 [TBL] [Abstract][Full Text] [Related]
16. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange. Waki Y; Nobeyama Y; Chujo S; Asahina A J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735 [No Abstract] [Full Text] [Related]
17. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077 [TBL] [Abstract][Full Text] [Related]
18. Pemphigoid nodularis associated with pembrolizumab in a lung cancer patient. Yamamoto M; Hashimoto T; Okuzawa M; Yashiki K; Okuno S; Awatani-Yoshidome K; Akaishi N; Satoh T Eur J Dermatol; 2023 Feb; 33(1):53-54. PubMed ID: 37178038 [No Abstract] [Full Text] [Related]
19. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer. Boozalis E; Kwatra SG; Marrone KA JAMA Oncol; 2019 Feb; 5(2):261-262. PubMed ID: 30286225 [No Abstract] [Full Text] [Related]
20. Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer. Kerkemeyer KLS; Lai FYX; Mar A Australas J Dermatol; 2020 May; 61(2):180-182. PubMed ID: 31808542 [No Abstract] [Full Text] [Related] [Next] [New Search]